FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

July 11, 2018 – The FDA granted an accelerated approval to the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan. The approval is based on results from a cohort of 119 patients with MSI-H or dMMR mCRC treated with the combination … (leggi tutto)